Caremark-CVS Deal Under Scrutiny

Shareholders are given more time to consider the merger in light of new information about the terms of the agreement

In its initial offer to acquire Caremark Rx (CMX), CVS Corp. (CVS) agreed to substantially boost premiums for insurance that would protect Caremark management and directors from charges of improper backdating of options. The disclosure, made by Caremark in a regulatory filing Feb. 12, bolstered accusations that the company accepted an inadequate takeover bid to get indemnity protection.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.